2-(6-溴-2-吡啶基)乙胺 | 404034-81-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 2-(6-溴-2-吡啶基)乙胺
• 中文别名: 2-(6-溴吡啶-2-基)乙胺
• 英文名称: 2-(6-bromopyridin-2-yl)ethylamine
• 英文别名: 2-(6-bromopyridin-2-yl)ethan-1-amine；2-(6-Bromopyridin-2-YL)ethanamine
• CAS: 404034-81-7
• 化学式: C₇H₉BrN₂
• 分子量: 201.066
• InChiKey: SPZHBKMCZADCIW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  2-(6-溴-2-吡啶基)乙胺 在 bis-triphenylphosphine-palladium(II) chloride 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 18.0h， 生成 {2-[6-(4-cyanobutyl)pyridin-2-yl]ethyl}phosphoramidic acid diethyl ester
  参考文献：
  名称：

  Palladium(0)-Catalyzed Coupling of Organozinc Iodide Reagents with Bromopyridines:  Synthesis of Selectively Protected Pyridine-Containing Azamacrocycles

  摘要：

  The synthesis of azamacrocycles in which the ring nitrogens are regioselectively functionalized is described. An organozinc palladium(0)-catalyzed coupling with an appropriately functionalized bromopyridine generated a key intermediate, which was transformed in two steps to a desired precursor and subjected to an intramolecular N-alkylation to effect a macrocyclization affording selectively protected azamacrocycles 1-3.

  DOI：

  10.1021/jo0109523
• 作为产物：
  描述：

  (6-溴吡啶-2-基)乙腈 在 三氟化硼四氢呋喃络合物 作用下， 以 四氢呋喃 为溶剂， 反应 18.0h， 生成 2-(6-溴-2-吡啶基)乙胺
  参考文献：
  名称：

  Palladium(0)-Catalyzed Coupling of Organozinc Iodide Reagents with Bromopyridines:  Synthesis of Selectively Protected Pyridine-Containing Azamacrocycles

  摘要：

  The synthesis of azamacrocycles in which the ring nitrogens are regioselectively functionalized is described. An organozinc palladium(0)-catalyzed coupling with an appropriately functionalized bromopyridine generated a key intermediate, which was transformed in two steps to a desired precursor and subjected to an intramolecular N-alkylation to effect a macrocyclization affording selectively protected azamacrocycles 1-3.

  DOI：

  10.1021/jo0109523

文献信息

• Cognition enhancing derivatives of isoxazole triazoloindane GABA-A alpha 5 receptor subunit ligands
  申请人：——

  公开号：US20040058970A1

  公开（公告）日：2004-03-25

  The present invention relates to compounds of formula I: 1 in which R 1 is a linear group or a five membered heterocycle optionally fused to a phenyl ring, R 2 is a 5-membered heterocycle, R 3 is chosen from a range of substituents, m is 0-3 and n is 0 or 1; the compounds are generally inverse agonists at GABA-A receptors containing the alpha 5 subunit and so are useful in methods of enhancing cognition in subjects with diminished cognition in diseases such as Alzheimer's Disease.

  本发明涉及式I的化合物：其中R1是线性基团或者一个五元杂环，可选择地与苯环融合，R2是一个五元杂环，R3是从一系列取代基中选择的，m为0-3，n为0或1；这些化合物通常是GABA-A受体中含有α5亚基的逆激动剂，因此在增强认知的方法中对患有认知减退症如阿尔茨海默病的受试者是有用的。
• NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS
  申请人：Bessis Anne-Sophie

  公开号：US20090124625A1

  公开（公告）日：2009-05-14

  The present invention relates to novel compounds of formula (I) wherein W, n, X and W′ are defined in the description; invention compounds are modulators of metabotropic glutamate receptors—subtype 5 (“mGluR5”) which are useful for the treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.

  本发明涉及化合物的新型配方（I），其中W，n，X和W′在说明书中定义；发明的化合物是代谢型谷氨酸受体-亚型5（“mGluR5”）的调节剂，可用于治疗中枢神经系统疾病以及其他受mGluR5受体调节的疾病。
• Pyridine, pyrimidine and pyrazine derivatives as gpcr agonists
  申请人：Bradley Stuart Edward

  公开号：US20100035897A1

  公开（公告）日：2010-02-11

  Compounds of formula (I): R 1 -A-V—B—R 2 , wherein V is phenyl or a 6-membered heteroaryl ring containing up to three N-atoms, or pharmaceutically acceptable salts thereof, are agonists of GPR116 and are useful for the treatment of obesity, and for the treatment of diabetes.

  式(I)的化合物：R1-A-V—B—R2，其中V为苯基或含有最多三个氮原子的6元杂环芳基环，或其药学上可接受的盐，是GPR116的激动剂，可用于治疗肥胖症和糖尿病。
• NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
  申请人：Bessis Anne-Sophie

  公开号：US20120277237A1

  公开（公告）日：2012-11-01

  The present invention relates to novel compounds of formula I wherein W, n, X and W′ are defined in the description; invention compounds are modulators of metabotropic glutamate receptors—subtype 5 (“mGluR5”) which are useful for the treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.

  本发明涉及一种新型化合物，其化学式为I，其中W、n、X和W′在说明中有定义；发明化合物是代谢型谷氨酸受体-亚型5（“mGluR5”）的调节剂，可用于治疗中枢神经系统疾病以及其他受mGluR5受体调节的疾病。
• Alkynyl derivatives as modulators of metabotropic glutamate receptors
  申请人：Addex Pharma SA

  公开号：EP2426115A2

  公开（公告）日：2012-03-07

  The present invention relates to novel compounds of formula I wherein W, n, X and W' are defined in the description; invention compounds are modulators of metabotropic glutamate receptors - subtype 5 ("mGluR5") which are useful for the treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.

  本发明涉及式 I 的新型化合物，其中 W、n、X 和 W' 在描述中定义；本发明化合物是代谢谷氨酸受体-亚型 5（"mGluR5"）的调节剂，可用于治疗中枢神经系统疾病以及受 mGluR5 受体调节的其他疾病。